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Abstract
Objective—To estimate summary standardized incidence ratios (SIRs) of non-AIDS cancers
among HIV-infected individuals compared to general population rates overall and stratified by
gender, AIDS and highly active antiretroviral therapy (HAART) era.
Design—A meta-analysis using SIRs from 18 studies of non-AIDS cancer in HIV-infected
individuals.
Methods—SIRs for non-AIDS cancers in HIV-infected individuals and 95% confidence limits (CL)
were abstracted from each study. Random effects meta-analyses were used to estimate summary
SIRs. Modification by gender, AIDS and HAART era were estimated with meta-regression.
Results—4,797 non-AIDS cancers occurred among 625,716 HIV-infected individuals. SIRs for
several cancers were elevated. In particular, cancers associated with infections, such as anal (SIR=28;
95% CL 21, 35), liver (SIR=5.6; 95% CL 4.0, 7.7) and Hodgkin lymphoma (SIR=11; 95% CL 8.8,
15), and smoking, such as lung (SIR=2.6; 95% CL 2.1, 3.1), kidney (SIR=1.7; 95% CL 1.3, 2.2) and
laryngeal (SIR=1.5; 95% CL 1.1, 2.0). AIDS was associated with greater SIRs for Hodgkin
lymphoma, leukemia, lung, brain and all non-AIDS cancers combined.
Conclusions—HIV-infected individuals may be at an increased risk of developing non-AIDS
cancers, particularly those associated with infections and smoking. An association with advanced
immune suppression was suggested for certain cancers.
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INTRODUCTION
Kaposi’s sarcoma, non-Hodgkin’s lymphoma and cervical cancer incidence rates in HIV-
infected individuals are significantly greater than rates in the general population1, and are
considered to be AIDS-defining illnesses by the Centers for Disease Control and
Prevention2. However, less is known about the incidence of non-AIDS-defining cancers among
those infected with HIV. Standardized incidence ratios (SIRs) comparing rates of all non-AIDS
cancers combined in HIV-infected individuals to the general population have ranged from
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essentially null to almost three3–14. Additionally, the SIRs of specific types of non-AIDS
cancers among HIV-infected individuals have been examined in several studies, though these
estimates are often imprecise with a limited number of cases of each cancer site. A recent meta-
analysis of incident non-AIDS cancers in HIV-infected individuals compared to the general
population included seven studies and examined specific cancers15. The SIRs were found to
be elevated among HIV-infected individuals for many cancer sites, particularly for those with
a confirmed or suspected infectious etiology. Our study includes an additional six studies (not
included in the prior meta-analysis) to examine SIRs from 13 studies for each cancer site, and
for all non-AIDS cancers combined. We also present stratified SIRs for non-AIDS cancers to
examine differences by gender, AIDS and highly active antiretroviral therapy (HAART) era.
METHODS
Search Strategy and Inclusion Criteria
Published articles were eligible for inclusion if they met two criteria. First, the article had to
include a comparison of the incidence of non-AIDS cancers in HIV-infected individuals and
the general population, estimated by SIR. The general population data was obtained from either
a cancer registry or Surveillance Epidemiology and End Results (SEER). Second, the article
had to provide data that did not overlap with other published studies. The search terms “HIV”
or “AIDS,” and “cancer,” and “SIR” or “incidence”, as well as specific cancer sites (i.e., “lung,”
“anal,” “prostate”) were used to identify potential articles in PubMed and EMBASE.
Additionally, the references of articles identified as relevant were searched for studies that may
have been missed. Searches were conducted between November 2007 and March 2009.
Statistical Analysis
SIRs and their 95% confidence limits (CLs) for all non-AIDS cancer sites among HIV-infected
individuals compared to the general population were abstracted from each study. Some of the
studies3, 4, 6, 7, 12–14, 16–18 only reported SIRs and 95% CLs to one decimal place, perhaps
limiting our ability to faithfully represent the existing evidence to a small extent by the
introduction of rounding error. In three studies, SIRs were reported stratified by gender,
calendar period or gender and calendar period without a combined estimate4, 8, 10, 19, and were
treated as separate stratum-specific studies in our analysis. Study-specific standard error
estimates for the natural logarithm of the SIR were obtained as σj = (ln aj −ln SIRj)/1.96, where
aj is the upper 95% CL, respectively, and j = 1 to J indexes the studies. A funnel plot (of
 by ln (SIRj)) for each cancer site was created to graphically assess the potential for
publication bias. We analyzed asymmetry in the funnel plot by calculating P-values for the
departure of the intercept from zero in a regression of 1/σj on ln (SIRj)/σj, as described by Egger
et al.20, and for the rank correlation between the study-specific SIRs and their variances, as
described by Begg and Mazumdar21. Funnel plot asymmetry was also examined with Duval
and Tweedie’s trim and fill method22, a simple imputation method that assumes that any
asymmetry is due to publication bias. Heterogeneity between studies was examined by
calculating a P-value for Cochran’s Q, namely , where ln
(SĪR) is the inverse-variance weighted average log SIR, and is distributed as χ2 with J-1 degrees
of freedom.
We estimated a random-effects summary SIR and 95% CL for each cancer site and all non-
AIDS cancers combined. Empirical Bayes estimates of each SIR were then calculated by using
hierarchical shrinkage to reduce overall error23. Additionally, stratum-specific random effects
SIRs were estimated separately for men and women, those with and without AIDS, and for the
pre-HAART and HAART eras. Modifications of the SIR (ratio of SIRs and 95% CLs) by these
variables were estimated in separate models by meta-regression of gender, AIDS and HAART
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era on the ln(SIR) using random-effects inverse-variance weighted linear regression with the
among-study variance estimated by restricted maximum likelihood. Only those studies that
reported estimates stratified by or restricted to one strata of gender4, 6, 10, 12, 14, 19, 24, 25,
AIDS6, 7, 11, 14, 26 or HAART era3–5, 8, 12, 17–19, 24 were included in stratum-specific SIRs
and meta-regression models. Though mean age was reported in most of the publications, it was
inconsistently reported as either the mean age of those with cancer or the mean age of the entire
HIV-infected cohort, thus we were unable to include age as a covariate in meta-regression.
Additionally, we were unable to include gender, AIDS and HAART era in the same model, as
the studies did not provide results stratified by all three factors.
All analyses were carried out using STATA version 8.2 and all graphs were generated in SAS
version 9.1.
RESULTS
Forty-two studies were identified for potential inclusion. Twenty-six studies were excluded
due to their data overlapping with either a larger study or more recently published study5, 7,
9, 12, 24–47. One study was excluded for using comparison data from a source other than SEER
or cancer registries 35, two other studies were excluded for not presenting SIRs48, 49, and the
remaining 13 were included in the overall meta-analysis. An additional five studies excluded
from the overall meta-analysis were included in the stratified analyses for gender12, 25 AIDS
status7, 26, and HAART era5. Though the data from these three studies overlapped with data
from larger studies4, 8, 14 these studies presented stratum-specific estimates which the original
publications did not, and thus were not included in these stratum-specific meta-analyses and
meta-regressions.
Of the 18 studies included in these analyses, nine were carried out in Europe3–7, 10, 14, 16,
19, seven in the United States8, 12, 17, 18, 24–26, one in Australia11, and one in Uganda13 (table
1). The mean age of study participants ranged from 28 to 48 years. Most results were for both
genders combined, with men predominating (33–94%). Five studies were confined to
women10, 12, 19, 25, 49 and four to men10, 19, 25, 49. Data on HIV-infected individuals were
obtained from AIDS registries in five studies4, 7, 8, 10, 25, HIV/AIDS registries in six
studies3, 11, 13, 14, 24, 26, prospective cohorts in six studies5, 6, 12, 16–18, and a hospital database
in one study19. Three studies used SEER data to calculate the number of expected cases12, 17,
18, and the remaining studies used data from country-specific cancer registries. All of the
studies used age- and sex-specific population incidence estimates. Additionally, several studies
used race-8, 12, 17, 18, 25, 26, calendar year/period-3–6, 8, 13, 18, 26, 33, registry-6, 8, 26 or region-
specific10, 25, 33 incidence rates.
Funnel plot asymmetry was not indicated by visual inspection, the tests of Eggar et al. or Begg
and Mazumdar, or Duval and Tweedie’s trim and fill method for the majority of cancer sites
(table 1). However, funnel plot asymmetry was suggested for the following cancer sites:
pancreatic cancer (p-values: 0.2 and 0.05, respectively), prostate cancer (p-values: 0.1 and 0.05,
respectively), rectal cancer (p-values: 0.3 and 0.05, respectively), melanoma (p-values: 0.2 and
0.07, respectively) and multiple myeloma (p-values: 0.05 and 0.05, respectively) by the tests
of Eggar et al. and Begg and Mazumdar. Additionally, the trim and fill method imputed
hypothetical missing results for the following cancer sites: lung, prostate, brain, multiple
myeloma, pancreas, penis and small intestine. With the imputed studies included, the changes
in each SIR did not change inferences. Most studies had a change in SIR of <0.4 (range: 0.06
to 0.36), with the exception of penile cancer (change in SIR: 1.68). Pronounced heterogeneity
was observed in well over half of the cancer sites. For example, for all non-AIDS cancers
combined this heterogeneity (Cochran’s Q=115; p-value<0.001) is illustrated by the ability to
find three separate estimates with no overlap among their 95% confidence intervals (e.g., the
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estimate for women on HAART from Herida et al.19 and the estimates for both genders
combined from Grulich et al.11 and Clifford et al.6).
In over one million person-years of follow-up from the 13 studies, a total of 4,797 non-AIDS
cancer cases were identified for inclusion in the overall meta-analysis. The most frequently
observed non-AIDS cancer type was lung cancer (n=847), followed by Hodgkin lymphoma
(n=643), and anal cancer (n=254). Many types of cancer were found to be substantially elevated
among HIV-infected individuals when compared to the general population (table 2). In
particular, many cancers associated with infections were observed to be elevated among HIV-
infected individuals, including cancers of the anus (SIR=28; 95% CL 21, 35), oropharynx
(SIR=1.9; 95% CL 1.4, 2.6), liver (SIR=5.6; 95% CL 4.0, 7.7), stomach (SIR=1.7; 95% CL
1.2, 2.5), and Hodgkin lymphoma (SIR=11; 95% CL 8.8, 15). The incidence rates of certain,
but not all, cancers associated with cigarette smoking, such as lung (SIR=2.6; 95% CL 2.1,
3.1), kidney (SIR=1.7; 95% CL 1.3, 2.2) and laryngeal cancers (SIR=1.5; 95% CL 1.1, 2.0)
were also observed to be elevated among HIV-infected individuals. Additionally, HIV-infected
individuals were observed to have substantially lower rates of breast (SIR=0.74; 95% CL 0.56,
0.97) and prostate (SIR=0.69; 95% CL 0.55, 0.86) cancers, when compared to the general
population. Overall, twice as many non-AIDS cancers were observed among those who were
HIV-infected, compared to the general population (SIR=2.0; 95% CL 1.8, 2.2).
When the ln(SIRs) for each cancer site were regressed on gender, the SIRs for lung cancer
(ratio of SIRs: 0.54; 95% CL 0.27, 1.1), kidney cancer (ratio of SIRs: 0.41; 95% CL 0.17, 1.01),
laryngeal cancer (ratio of SIRs: 0.26; 95% CL 0.11, 0.58), leukemia (ratio of SIRs: 0.43, 95%
CL 0.20, 0.92) and multiple myeloma (ratio of SIRs: 0.38; 95% CL 0.18, 0.80) appeared to be
less elevated among men than women (figure 1; appendix 2). However, the SIRs for all non-
AIDS cancers combined (ratio of SIRs: 1.59; 95% CL 1.23, 2.06) was greater among men than
women.
When ln(SIRs) were regressed on AIDS status, relative to those without AIDS, those with
AIDS had dramatically increased SIRs for leukemia (ratio of SIRs: 8.02; 95% CI 3.52, 18.25)
and brain cancer (ratio of SIRs: 4.86; 95% CI 1.22, 19.34) (figure 2; appendix 3). Those with
AIDS were observed to have three times the SIR of Hodgkin lymphoma (ratio of SIRs: 2.77;
95% CL 1.43, 5.37), lung cancer (ratio of SIRs: 3.01; 95% CL 1.69, 5.38), and all non-AIDS
cancers combined (ratio of SIRs: 3.17; 95% CL 1.42, 7.09), when compared to those without
AIDS. The SIRs for liver and laryngeal cancers also appeared to be more elevated among those
with AIDS than among those without AIDS. No difference was seen in SIRs by AIDS status
for anal cancer, non-melanoma skin cancer, melanoma, pancreatic cancer, or prostate cancer.
The AIDS case definition in the U.S. varies from the AIDS case definitions in Europe and
Australia, thus we examined the results stratified by AIDS with and without the U.S.
study26. As the stratified results were similar regardless of whether the U.S. study was included,
only the results including this study were presented.
Finally, when ln(SIRs) were regressed on HAART era, the SIRs for kidney cancer (ratio of
SIRs: 1.56, 95% CL 0.96, 2.54) and breast cancer (ratio of SIRs: 1.48; 95% CL 0.98, 2.23)
were observed to be increased in the HAART era compared to the pre-HAART era (figure 3;
appendix 4). The SIRs did not appear to be different for the remaining cancer sites by HAART
era, including for all non-AIDS cancers combined (ratio of SIRs: 0.94; 95% CL 0.59, 1.49).
DISCUSSION
We combined data from 18 studies (13 studies in overall meta-analysis, and 5 additional studies
included in stratified analyses) to estimate the relative incidence of specific non-AIDS cancers
among HIV-infected individuals, compared to the general population. HIV-infected
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individuals had twice the risk of a non-AIDS cancer than the general population. SIRs for all
non-AIDS cancers were greater among men than women and among those with AIDS than
those without AIDS; however, no substantial difference was observed by HAART era. The
random-effects SIRs showed a substantial increase in the incidence rate of many individual
cancer sites among those with HIV when compared to the general population. Additionally,
the SIRs for certain cancers seemed to be modified by gender, AIDS and HAART era. These
differences do not by themselves imply that the incidence rate of specific cancers is different
by gender, or HAART era, as the reference group of general population non-AIDS cancer
incidence may differ in these strata.
Though the body of research supporting an increased risk of non-AIDS cancers among HIV-
infected individuals continues to expand, explanations for this increase have not yet been well-
elucidated. HIV-associated immune suppression may increase susceptibility to cancers that are
caused by oncogenic viruses. Indeed, we observed the greatest SIRs to be in cancer sites that
have an infectious etiology. Anal, vaginal, penile, nasopharyngeal, laryngeal and oral cancers
are all associated with infection with human papillomavirus (HPV), and were all found to occur
at a greater rate among those infected with HIV than in the general population. Additionally,
liver cancer is associated with hepatitis B (HBV) and hepatitis C (HCV) virus, and
nasopharyngeal cancer and Hodgkin lymphoma are both associated with Epstein-Barr virus
(EBV); the incidence rates for these three cancer sites were all substantially higher in those
with HIV than in the general population. HIV-infected persons may be disproportionately
infected with oncogenic viruses. For example, in a study of homosexual men, HIV-infected
men were found to have 1.5 times the risk of anal HPV infection as HIV-uninfected men50,
and in a study of women at high risk for HIV, HIV-infected women were found to have 1.8
times the risk of anal HPV infection as HIV-uninfected women51. Conversely, several cancers
without strong evidence for an infectious etiology, such as colorectal and pancreatic cancers,
had summary SIRs that were near null. Decreased immune function paired with increased
incidence of these infections may be responsible for the increased rates of virally-associated
cancers among those infected with HIV. The association between decreased immune function
and increased risk of anal cancer, Hodgkin lymphoma and liver cancer is further supported by
our observation that the SIRs of these cancers were increased among those with AIDS
compared to those without AIDS. Furthermore, rates of anal cancer, Hodgkin lymphoma, and
liver cancer, as well as other cancers associated with oncogenic viruses have been found to be
elevated among organ transplant recipients, providing support for the role of suppressed
immunity in their etiology15.
HIV-infected individuals may also have a higher prevalence of other cancer risk factors (e.g.,
cigarette smoking) than the general population. One study reported the prevalence of cigarette
smoking to be 59% among persons with HIV/AIDS in New York State, which is three times
the prevalence in the general population52. Another study reported the prevalence of smoking
among all participants of the Swiss HIV Cohort Study to be 72%, and as high as 96% among
injection drug users in the cohort38. We observed elevated summary SIRs for several smoking-
related cancers, including lung, kidney, stomach, laryngeal and oral cancers. While some
studies suggest that the increased risk of lung cancer among HIV-infected individuals is likely
explained by differences in smoking6, 12, other studies have shown an increase in lung cancer,
even after accounting for differences in smoking40, 53. The SIRs for most smoking-related
cancers (lung, kidney, laryngeal, and stomach cancers) were observed to be greater among
women than men. Perhaps the greater SIR observed among women is due to a greater relative
increase in smoking among HIV-infected women compared to the general population
compared to HIV-infected men, though we did not have data to examine the prevalence of
cigarette smoking among men and women in each study. Interestingly, the SIR for lung cancer
was observed to be greater among those with AIDS than those without AIDS, suggesting that
immune suppression may play a role in the development of lung cancer among those who are
Shiels et al. Page 5













HIV-infected. It has been hypothesized that HIV-associated suppression of the immune system
may lead to reduced tumor surveillance, allowing tumors of the lung to continue to develop
when they otherwise would be destroyed by the immune system54, 55.
We observed the incidence of breast and prostate cancer to be lower among HIV-infected
women and men compared to the general population. This may suggest a potential protective
effect of HIV on the development of these cancers, perhaps through changes in hormone
levels42. However, the decreased incidence of these cancers among HIV-infected individuals
may also be due to differential screening by HIV status27, 42. Those with HIV, particularly
injection drug users and the poor, may be less likely to be regularly screened for cancers. For
example, the Women’s Interagency HIV Study found women with HIV and at high risk for
HIV were significantly less likely to have a mammogram than women in the general U.S.
population56. Therefore, more sub-clinical disease may be detected among those without HIV,
which would result in an increased incidence.
Our analyses were limited to the information provided by each of the included studies. We
were unable to look at other factors that may modify the association between HIV and non-
cancer AIDS, such as age, likely route of transmission, smoking status, or race/ethnicity. We
observed notable between-study heterogeneity; this heterogeneity may be due to differences
in study design, populations studied, or in unmeasured characteristics that may vary across
studies. Indeed, it is likely that one or more of these factors explains a portion of the observed
between-study heterogeneity. Additionally, we observed departures in symmetry for the funnel
plots of a few cancer sites, which may be due to publication bias.
The use of general population comparisons is a limitation of the literature, and thus of our
review of that literature. In occupational epidemiology, such external comparisons with general
populations are generally considered inferior to internal comparisons within employed
populations. The biases have been grouped under such rubrics as the "healthy worker" and
"healthy worker survivor" biases. The analog of internal comparisons in occupational studies
would be to compare HIV-infected individuals with and without AIDS directly, or to compare
HIV-infected men and women directly, rather than to compare the comparisons with the general
population.
Another limitation is the examination of effect-measure modification for ratio effect measures.
It may have been preferable to examine modification of rate differences57. Fortunately, the
indications are of a greater elevation of rate ratios in groups with higher baseline rates (HIV-
infected men and AIDS patients). In this case, positive rate ratio modification implies positive
rate difference modification.
Finally, for some cancer sites, our meta-analyses were based on very few cases from few
studies. Summary SIRs for nasopharyngeal, eye, bone, small intestine and gall bladder cancers
were all based on 10 cases or fewer, and summary SIRs for nasopharyngeal, eye, small intestine,
lip, oral and pharyngeal, oropharyngeal, gall bladder and rectal cancers were based on results
from only two or three studies. Thus, the estimates for these cancer sites are particularly
imprecise.
This work expands upon a previous meta-analysis that presented summary SIRs for non-AIDS
cancers among HIV-infected individuals15. In addition to the seven studies included in the
prior meta-analysis, we included six studies that have presented SIRs for non-AIDS cancers.
Additionally, our study differs from the prior meta-analysis in that we examined whether SIRs
differed by gender, AIDS status and HAART era, while the previous study did not. These
stratified analyses highlight differences in SIRs of non-AIDS cancers, relative to the general
population, that may be associated with gender, immune suppression and HAART use.
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This study found an increased general-population SIR for many types of non-AIDS cancers.
It remains unclear whether HIV-infected individuals are truly at a greater risk for non-AIDS-
defining cancers, or if confounding by unadjusted cancer risk factors may be responsible for
the apparent elevated incidence. Future pooling projects (rather than meta-analyses) that
compare HIV-infected to HIV-uninfected individuals will be better able to elucidate the effect
of HIV infection on the development of non-AIDS cancers.
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SIRs and (95% confidence limit)s for each study included in the overall meta-analysis.
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Random effects SIRs and ratio of SIRs by sex for non-AIDS cancers among HIV-infected individuals compared
to the general population.
Number of Studies SIR 95% CL
Anus Men 4 32 (22, 46)
Women 3 24 (12, 48)
Ratio of SIRs 1.33 (0.60, 2.97)
Skin Cancer Men 5 5.7 (2.5, 13)
Women 4 3.9 (2.0, 7.7)
Ratio of SIRs 1.45 (0.39, 5.46)
Hodgkin Lymphoma Men 7 15 (8.3, 26)
Women 6 8.4 (4.8, 15)
Ratio of SIRs 1.79 (0.83, 3.88)
Stomach Men 4 1.3 (0.55, 3.2)
Women 3 3.8 (1.2, 12)
Ratio of SIRs 0.35 (0.09, 1.34)
Lung Men 7 1.9 (1.4, 2.7)
Women 6 3.8 (2.5, 5.9)
Ratio of SIRs 0.54 (0.27, 1.1)
Kidney Men 4 1.2 (0.75, 1.9)
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Number of Studies SIR 95% CL
Women 4 3.0 (1.3, 6.7)
Ratio of SIRs 0.41 (0.17, 1.01)
Leukemia Men 4 1.5 (0.88, 2.7)
Women 4 3.8 (2.5, 5.7)
Ratio of SIRs 0.43 (0.20, 0.92)
Larynx Men 4 1.2 (0.84, 1.8)
Women 2 4.9 (2.5, 9.5)
Ratio of SIRs 0.26 (0.11, 0.58)
Melanoma Men 5 1.1 (0.68, 1.7)
Women 3 1.3 (0.62, 2.6)
Ratio of SIRs 0.84 (0.36, 1.99)
Brain Men 4 1.8 (1.2, 2.8)
Women 3 2.7 (1.7, 4.4)
Ratio of SIRs 0.66 (0.33, 1.33)
Multiple Myeloma Men 4 2.2 (1.4, 3.2)
Women 2 5.6 (2.9, 11)
Ratio of SIRs 0.38 (0.18, 0.80)
Thyroid Men 2 1.9 (0.31, 12)
Women 3 0.96 (0.51, 1.8)
Ratio of SIRs 2.31 (0.69, 7.69)
Colon Men 3 0.71 (0.55, 0.91)
Women 2 1.5 (0.24, 9.9)
Ratio of SIRs 0.47 (0.23, 0.94)
All non-AIDS cancers Men 6 2.3 (2.0, 2.7)
Women 7 1.5 (1.1, 1.8)
Ratio of SIRs 1.59 (1.23, 2.06)
Appendix
Appendix 3
Random effects SIRs and ratio of SIRs by AIDS status for non-AIDS cancers among HIV-infected individuals
compared to the general population.
Number of Studies SIR 95% CL
Anus No AIDS 5 20 (10, 38)
AIDS 4 31 (19, 52)
Ratio of SIRs 1.61 (0.65, 4.02)
Skin Cancer No AIDS 3 2.9 (1.4, 5.8)
AIDS 3 6.6 (0.40, 108)
Ratio of SIRs 2.77 (0.20, 37.71)
Hodgkin Lymphoma No AIDS 4 5.9 (3.3, 10)
AIDS 5 16 (12, 21)
Ratio of SIRs 2.77 (1.43, 5.37)
Liver No AIDS 2 3.9 (2.6, 5.6)
AIDS 5 6.5 (3.6, 12)
Ratio of SIRs 1.67 (0.82, 3.42)
Lung No AIDS 5 1.5 (0.82, 2.6)
AIDS 5 5.1 (4.0, 6.4)
Ratio of SIRs 3.01 (1.69, 5.38)
Leukemia No AIDS 3 0.9 (0.48, 1.9)
AIDS 3 7.5 (4.7, 12)
Ratio of SIRs 8.02 (3.52, 18.25)
Larynx No AIDS 2 2.1 (1.3, 3.6)
AIDS 3 3.6 (1.7, 7.6)
Ratio of SIRs 1.70 (0.69, 4.18)
Pancreas No AIDS 2 1.0 (0.14, 7.2)
AIDS 3 2.2 (0.92, 5.4)
Ratio of SIRs 1.13 (0.41, 3.15)
Prostate No AIDS 2 1.1 (0.57, 2.0)
AIDS 2 1.4 (0.27, 6.8)
Ratio of SIRs 1.29 (0.33, 5.09)
Melanoma No AIDS 2 0.39 (0.04, 4.1)
AIDS 2 0.44 (0.12, 1.7)
Ratio of SIRs 0.99 (0.07, 13.56)
Brain No AIDS 2 0.8 (0.27, 2.4)
AIDS 2 3.9 (1.6, 9.6)
Ratio of SIRs 4.86 (1.22, 19.34)
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Number of Studies SIR 95% CL
All non-AIDS cancers No AIDS 4 1.2 (0.66, 2.0)
AIDS 4 3.7 (2.0, 6.8)
Ratio of SIRs 3.17 (1.42, 7.09)
Appendix
Appendix 4
Random effects SIRs and ratio of SIRs by HAART era for non-AIDS cancers among HIV-infected individuals
compared to the general population.
Number of studies SIR 95% CL
Anus Pre-HAART Era 4 37 (19, 75)
HAART Era 5 47 (22, 100)
Ratio of SIRs 1.25 (0.48, 6.49)
Head and Neck Pre-HAART Era 3 1.6 (0.91, 2.9)
HAART Era 3 2.5 (1.1, 5.6)
Ratio of SIRs 1.54 (0.56, 4.29)
Hodgkin Lymphoma Pre-HAART Era 7 9.7 (6.2, 15)
HAART Era 6 19 (13, 27)
Ratio of SIRs 1.90 (1.11, 3.27)
Liver Pre-HAART Era 4 6.0 (2.8, 13)
HAART Era 5 7.5 (4.2, 14)
Ratio of SIRs 1.25 (0.49, 3.24)
Stomach Pre-HAART Era 4 3.0 (1.2, 7.5)
HAART Era 4 1.6 (1.1, 2.3)
Ratio of SIRs 0.55 (0.21, 1.44)
Lung Pre-HAART Era 6 2.0 (1.2, 3.3)
HAART Era 6 3.5 (2.6, 4.6)
Ratio of SIRs 1.78 (0.99, 3.22)
Kidney Pre-HAART Era 3 1.2 (0.81, 1.8)
HAART Era 4 1.9 (1.3, 2.8)
Ratio of SIRs 1.56 (0.96, 2.54)
Larynx Pre-HAART Era 3 1.3 (0.78, 2.1)
HAART Era 2 1.7 (0.64, 4.4)
Ratio of SIRs 1.45 (0.54, 3.92)
Esophagus Pre-HAART Era 2 1.4 (0.30, 6.1)
HAART Era 4 1.8 (0.77, 4.4)
Ratio of SIRs 1.38 (0.26, 7.46)
Bladder Pre-HAART Era 4 1.3 (0.66, 2.6)
HAART Era 3 1.2 (0.35, 3.8)
Ratio of SIRs 0.82 (0.22, 3.11)
Colorectal Pre-HAART Era 2 1.4 (0.46, 4.3)
HAART Era 3 1.2 (0.63, 2.2)
Ratio of SIRs 0.82 (0.25, 2.75)
Prostate Pre-HAART Era 4 0.49 (0.32, 0.75)
HAART Era 5 0.56 (0.44, 0.72)
Ratio of SIRs 1.14 (0.77, 1.69)
Melanoma Pre-HAART Era 5 1.2 (0.86, 1.6)
HAART Era 6 1.5 (0.90, 2.4)
Ratio of SIRs 1.29 (0.71, 2.32)
Breast Pre-HAART Era 5 0.43 (0.31, 0.59)
HAART Era 6 0.64 (0.50, 0.82)
Ratio of SIRs 1.48 (0.98, 2.23)
Testis Pre-HAART Era 4 1.4 (1.0, 1.9)
HAART Era 3 1.0 (0.49, 2.2)
Ratio of SIRs 0.74 (0.39, 1.32)
Brain Pre-HAART Era 3 1.9 (0.66, 5.7)
HAART Era 3 1.0 (0.63, 1.7)
Ratio of SIRs 0.56 (0.16, 1.91)
Multiple Myeloma Pre-HAART Era 3 2.5 (1.3, 4.6)
HAART Era 3 2.6 (1.7, 4.1)
Ratio of SIRs 1.11 (0.60, 2.05)
Uterus Pre-HAART Era 2 1.5 (0.35, 6.2)
HAART Era 3 0.65 (0.28, 1.5)
Ratio of SIRs 0.46 (0.10, 2.03)
All non-AIDS cancers Pre-HAART Era 4 1.9 (1.6, 2.4)
HAART Era 3 1.7 (1.4, 2.1)
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Number of studies SIR 95% CL
Ratio of SIRs 0.89 (0.62, 1.28)
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Summary standardized incidence ratios (SIRs) and 95% confidence limits for specific types
of non-AIDS cancer, by gender.
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men
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Summary standardized incidence ratios (SIRs) and 95% confidence limits for specific types
of non-AIDS cancer, by AIDS status.
No AIDS
AIDS
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Summary standardized incidence ratios (SIRs) and 95% confidence limits for specific types
of non-AIDS cancer, by Highly Active Antiretroviral Therapy (HAART) era.
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Table 1
Characteristics of 18 studies of the incidence of non-AIDS cancers among HIV-infected populations when
compared to the general population.
First author Years Country Populationcomparison
Non-AIDS
cancer cases
Cooksley24 1981–1984 United States Cancer Registry 330
Gallagher*25 1981–1994 United States Cancer Registry 1,569
Grulich11 1985–1998 Australia Cancer Registry 196
Herida19 1992–1999 France Cancer Registry 651
Dal Maso**7 1985–1998 Italy Cancer Registry 170
Allardice3 1981–1996 Scotland Cancer Registry 24
Hessol*12 1993–2001 United States SEER 22
Clifford6 1985–2002 Switzerland Cancer Registry 132
Newnham14 1985–2001 England Cancer Registry 442
Mbulaiteye13 1989–2002 Uganda Cancer Registry 60
Engels8 1980–2002 United States Cancer Registry 1,627
Galceran10 1981–1999 Spain Cancer Registry 22
Serranio16 1985–2005 Italy and France Cancer Registry 107
Long18 1996–2005 United States SEER 115
Patel17 1992–2003 United States SEER 708
Engels**26 1991–2002 United States Cancer Registry 461
Powles***5 1983–2007 England Cancer Registry 156
Dal Maso4 1986–2004 Italy Cancer Registry 383
*
Data included in gender-stratified meta-analysis only.
**
Data included in AIDS-stratified meta-analysis only.
***
Data included in HAART era-stratified meta-analysis only.
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